1. Inhibitory effects of arresten on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cells.

    Current Eye Research 35(1):45 (2010) PMID 20021254 PMCID PMC2827929

    The potential role of arresten (alpha1(IV)NC1) as an endogenous angiogenesis inhibitor in the prevention of bFGF mediated retinal angiogenesis and regulation of matrix metalloproteinase-2 activation has not been explored. Mouse retinal endothelial cells (MREC) were cultured on type IV collagen a...
  2. Inhibitory effects of arresten on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cells.

    Current Eye Research 35(1):45 (2010) PMID 20021254 PMCID PMC2827929

    The potential role of arresten (alpha1(IV)NC1) as an endogenous angiogenesis inhibitor in the prevention of bFGF mediated retinal angiogenesis and regulation of matrix metalloproteinase-2 activation has not been explored. Mouse retinal endothelial cells (MREC) were cultured on type IV collagen a...
  3. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.

    PLoS ONE 5(8):e12029 (2010) PMID 20808434 PMCID PMC2922327

    Weak intermolecular interactions such as hydrogen bonding and hydrophobic interactions are key players in stabilizing energetically-favored ligands, in an open conformational environment of protein structures. However, it is still poorly understood how the binding parameters associated with thes...
  4. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.

    PLoS ONE 5(8):e12029 (2010) PMID 20808434 PMCID PMC2922327

    Weak intermolecular interactions such as hydrogen bonding and hydrophobic interactions are key players in stabilizing energetically-favored ligands, in an open conformational environment of protein structures. However, it is still poorly understood how the binding parameters associated with thes...
  5. FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1.

    Investigative Ophthalmology & Visual Science 50(10):4567 (2009) PMID 19443723 PMCID PMC2795568

    To determine the impact of the antiangiogenic factor alpha1(IV)NC1 on vascular endothelial growth factor-mediated proangiogenic activity in mouse retinal endothelial cells (MRECs). Primary culture of MRECs was established as previously described and was used to determine the effects of alpha1(IV...
  6. FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1.

    Investigative Ophthalmology & Visual Science 50(10):4567 (2009) PMID 19443723 PMCID PMC2795568

    To determine the impact of the antiangiogenic factor alpha1(IV)NC1 on vascular endothelial growth factor-mediated proangiogenic activity in mouse retinal endothelial cells (MRECs). Primary culture of MRECs was established as previously described and was used to determine the effects of alpha1(IV...
  7. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.

    Pharmaceutical Research 25(12):2731 (2008) PMID 18551250

    Growing tumors develop additional new blood vessels to meet the demand for adequate nutrients and oxygen, a process called angiogenesis. Cancer is a highly complex disease promoted by excess angiogenesis; interfering with this process poses for an attractive approach for controlling tumor growth...
  8. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.

    Pharmaceutical Research 25(12):2731 (2008) PMID 18551250

    Growing tumors develop additional new blood vessels to meet the demand for adequate nutrients and oxygen, a process called angiogenesis. Cancer is a highly complex disease promoted by excess angiogenesis; interfering with this process poses for an attractive approach for controlling tumor growth...
  9. Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor.

    Experimental Cell Research 314(18):3292 (2008) PMID 18775695 PMCID PMC2613512

    Physiological and pathological turnover of basement membranes liberates biologically active cryptic molecules. Several collagen-derived fragments possess anti-angiogenic activity. Arresten is the 26-kDa non-collagenous domain of type IV collagen alpha1 chain. It functions as an efficient inhibit...
  10. Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor.

    Experimental Cell Research 314(18):3292 (2008) PMID 18775695 PMCID PMC2613512

    Physiological and pathological turnover of basement membranes liberates biologically active cryptic molecules. Several collagen-derived fragments possess anti-angiogenic activity. Arresten is the 26-kDa non-collagenous domain of type IV collagen alpha1 chain. It functions as an efficient inhibit...
  11. Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor.

    Experimental Cell Research 314(18):3292 (2008) PMID 18775695 PMCID PMC2613512

    Physiological and pathological turnover of basement membranes liberates biologically active cryptic molecules. Several collagen-derived fragments possess anti-angiogenic activity. Arresten is the 26-kDa non-collagenous domain of type IV collagen alpha1 chain. It functions as an efficient inhibit...
  12. Characterization of the anti-angiogenic properties of arresten, an α1β1 integrin-dependent collagen-derived tumor suppressor

    Experimental Cell Research 314(18):3292 (2008) PMID 18775695 PMCID PMC2613512

    Physiological and pathological turnover of basement membranes liberates biologically active cryptic molecules. Several collagen-derived fragments possess anti-angiogenic activity. Arresten is the 26-kDa non-collagenous domain of type IV collagen α1 chain. It functions as an efficient inhibi...
  13. Molecular Cloning and Functional Characterization of Mouse α3(IV)NC1.

    Clinical medicine. Oncology 2:73 (2008) PMID 21892268 PMCID PMC3161651

    Non-collagenous α3 chain of type IV collagen or α3(IV)NC1, a 28 kDa C-terminal domain of collagen type IV is a specific inhibitor of endothelial cell translation and angiogenesis. In the present study we have cloned and expressed mouse α3(IV)NC1 in baculovirus system. The recombinant protein was...
  14. Molecular Cloning and Functional Characterization of Mouse α3(IV)NC1.

    Clinical medicine. Oncology 2:73 (2008) PMID 21892268 PMCID PMC3161651

    Non-collagenous α3 chain of type IV collagen or α3(IV)NC1, a 28 kDa C-terminal domain of collagen type IV is a specific inhibitor of endothelial cell translation and angiogenesis. In the present study we have cloned and expressed mouse α3(IV)NC1 in baculovirus system. The recombinant protein was...
  15. Characterization of the anti-angiogenic properties of arresten, an α1β1 integrin-dependent collagen-derived tumor suppressor

    Experimental Cell Research 314(18):3292 (2008)

    Physiological and pathological turnover of basement membranes liberates biologically active cryptic molecules. Several collagen-derived fragments possess anti-angiogenic activity. Arresten is the 26-kDa non-collagenous domain of type IV collagen α1 chain. It functions as an efficient inhibi...
  16. Regulation of caspase-3 mediated apoptosis and tumor angiogenesis

    Matrix Biology 27:18 (2008)

  17. Regulation of caspase-3 mediated apoptosis and tumor angiogenesis

    Matrix Biology 27:18 (2008)

  18. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.

    Blood 110(4):1168 (2007) PMID 17426256 PMCID PMC1939900

    Human alpha3 chain, a noncollagenous domain of type IV collagen [alpha3(IV)NC1], inhibits angiogenesis and tumor growth. These biologic functions are partly attributed to the binding of alpha3(IV)NC1 to alphaVbeta3 and alpha3beta1 integrins. alpha3(IV)NC1 binds alphaVbeta3 integrin, leading to t...
  19. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.

    Blood 110(4):1168 (2007) PMID 17426256 PMCID PMC1939900

    Human alpha3 chain, a noncollagenous domain of type IV collagen [alpha3(IV)NC1], inhibits angiogenesis and tumor growth. These biologic functions are partly attributed to the binding of alpha3(IV)NC1 to alphaVbeta3 and alpha3beta1 integrins. alpha3(IV)NC1 binds alphaVbeta3 integrin, leading to t...
  20. Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen.

    Gene Regulation and Systems Biology 1:217 (2007) PMID 19936090 PMCID PMC2759143

    Vascular basement membrane (VBM) derived molecules are regulators of certain biological activities such as cell growth, differentiation and angiogenesis. Angiogenesis is regulated by a systematic controlled balance between VBM derived antiangiogenic factors and proangiogenic growth factors. In t...